Breaking Down Barriers in Cancer Detection: Gencurix and Roche Diagnostics Korea Join Forces for a Diagnostic Revolution
+ Development of digital PCR-based cancer diagnostic product (IVD) and commercialization goal in 2026
Cancer molecular diagnosis company Gencurix (229000) signed a partnership agreement with Roche Diagnostics Korea, the Korean subsidiary of Roche Diagnostics, a global leading company in the field of in vitro diagnostics, to develop and commercialize a cancer diagnostic kit using digital polymerase chain reaction (digital PCR) technology. did it
This agreement is aimed at a long-term strategic partnership to strengthen competitiveness in the cancer diagnosis market by combining Gencurix’s digital PCR molecular diagnostic development and innovation capabilities with Roche Diagnostics Korea’s in vitro diagnostic (IVD) business experience.
Through this agreement, the two companies plan to cooperate in four major areas: ▲ joint market research ▲ product development and raw material supply ▲ response to licensing and insurance application regulations ▲ commercialization activities. In the cancer diagnosis field, we will first pursue molecular diagnostic products for the diagnosis and treatment monitoring of non-small cell lung cancer and breast cancer, and will also expand into testing methods to address unmet needs for the diagnosis of other diseases. Representative products planned for joint development include a multiplex digital PCR-based lung cancer panel diagnostic kit and a PIK3CA companion diagnostic kit that can predict response to PI3K inhibitors revealed in the breast cancer INAVO 120 clinical study.
Gencurix CEO Cho Sang-rae said, “Gencurix is the world’s first company to develop a digital PCR-based cancer companion diagnostic kit. Through this collaboration with Roche Diagnostics, Gencurix’s products will enter the global liquid biopsy and digital PCR diagnostic market as well as the domestic market. “We have established an important bridgehead for advancement,” he emphasized.
Kit Tang, CEO of Roche Diagnostics Korea, said, “This collaboration with Gencurix will be an important step in enabling more patients to use the latest technology in cancer diagnosis,” and “It will accelerate innovation in the field of cancer diagnosis.” said.
With this agreement, both companies will strengthen their positions in the cancer diagnosis market and focus on providing innovative diagnostic technologies to patients.